HC Wainwright Has Positive Estimate for XOMA Q2 Earnings

XOMA Co. (NASDAQ:XOMA - Free Report) - Equities research analysts at HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for XOMA in a note issued to investors on Wednesday, May 28th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of $0.06 for the quarter, up from their previous forecast of ($0.13). HC Wainwright has a "Buy" rating and a $104.00 price target on the stock. The consensus estimate for XOMA's current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for XOMA's Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.39 EPS, FY2025 earnings at $0.62 EPS and FY2026 earnings at $1.16 EPS.

A number of other equities research analysts have also recently commented on XOMA. Benchmark began coverage on XOMA in a research note on Thursday, April 17th. They set a "buy" rating and a $35.00 target price on the stock. Wall Street Zen upgraded XOMA from a "hold" rating to a "buy" rating in a research note on Friday.

XOMA Stock Performance

NASDAQ:XOMA traded up $0.74 during trading on Friday, reaching $24.96. The company's stock had a trading volume of 7,199 shares, compared to its average volume of 37,305. XOMA has a 12 month low of $18.35 and a 12 month high of $35.00. The firm has a market cap of $298.70 million, a price-to-earnings ratio of -7.17 and a beta of 0.89. The firm has a 50 day moving average of $22.99 and a 200-day moving average of $24.99. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

XOMA (NASDAQ:XOMA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.32. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The company had revenue of $15.91 million for the quarter, compared to analyst estimates of $6.75 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC lifted its position in XOMA by 1,063.8% in the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 1,585 shares during the last quarter. New York State Common Retirement Fund raised its holdings in shares of XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock valued at $62,000 after acquiring an additional 800 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of XOMA by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock valued at $113,000 after acquiring an additional 1,183 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of XOMA by 5,087.9% during the first quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 6,309 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of XOMA by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock valued at $205,000 after acquiring an additional 2,009 shares in the last quarter. Hedge funds and other institutional investors own 95.92% of the company's stock.

Insider Buying and Selling at XOMA

In other news, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the business's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the completion of the transaction, the insider now owns 1,267,545 shares of the company's stock, valued at approximately $34,350,469.50. The trade was a 23.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Joseph M. Limber acquired 17,935 shares of the business's stock in a transaction dated Thursday, April 3rd. The shares were acquired at an average cost of $25.24 per share, with a total value of $452,679.40. Following the acquisition, the director now directly owns 16,524 shares of the company's stock, valued at $417,065.76. This represents a -1,271.08% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 29,312 shares of company stock valued at $735,061 in the last quarter. 9.10% of the stock is currently owned by corporate insiders.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.